Home > Insider Trading > Filing (0001179110-21-007353)

Filing Details

Accession Number:: 0001179110-21-007353
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-07-02 21:15:34
Reporting Period:: 2021-07-01

Accepted Time:: 2021-07-02 21:15:34
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1280600	Acceleron Pharma Inc	XLRN	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1690773	J Habib Dable	128 Sidney Street Cambridge MA 02139	Ceo And President	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-07-01	57,814	$35.04	156,264	No	4	M	Direct
Common Stock	Disposition	2021-07-01	11,845	$125.15	144,419	No	4	S	Direct
Common Stock	Disposition	2021-07-01	9,194	$125.81	135,225	No	4	S	Direct
Common Stock	Disposition	2021-07-01	23,160	$126.85	112,065	No	4	S	Direct
Common Stock	Disposition	2021-07-01	4,560	$127.89	107,505	No	4	S	Direct
Common Stock	Disposition	2021-07-01	9,055	$128.82	98,450	No	4	S	Direct
Common Stock	Acquisiton	2021-07-02	42,186	$35.04	140,636	No	4	M	Direct
Common Stock	Disposition	2021-07-02	29,140	$126.69	111,496	No	4	S	Direct
Common Stock	Disposition	2021-07-02	11,458	$127.51	100,038	No	4	S	Direct
Common Stock	Disposition	2021-07-02	1,588	$128.21	98,450	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Option to Purchase Common Stock	Disposition	2021-07-01	57,814	$0.00	57,814	$35.04
Common Stock	Option to Purchase Common Stock	Disposition	2021-07-02	42,186	$0.00	42,186	$35.04

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
292,186		2026-12-01	No	4	M	Direct
250,000		2026-12-01	No	4	M	Direct

Footnotes

The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.41 to $125.36 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.42 to $126.41 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.42 to $127.40 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.44 to $128.40 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.53 to $129.14 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (6) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.10 to $127.09 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (7) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.13 to $128.09 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (8) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.13 to $128.77 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (9) to this Form 4.
The shares of common stock underlying this stock option award vested as to 25% of the shares on the first anniversary of December 1, 2016 and the remaining shares vested in equal quarterly installments over the following three years thereafter.